Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17672450 | 0.89 | LTA4H (0.37) | NAAALTA4HPTGS2KDM4ECYP2D6 | |
| SCHEMBL1376316 | 0.80 | — | — | |
| SCHEMBL18263363 | 0.79 | NAAA (0.39) | NAAALTA4HPTGS2KDM4ECYP2D6 | |
| SCHEMBL4273388 | 0.79 | CYP2D6 (0.54) | NAAALTA4HPTGS2KDM4ECYP2D6 | |
| SCHEMBL29415405 | 0.78 | NAAA (0.41) | NAAALTA4HPTGS2KDM4ECYP2D6 | |
| SCHEMBL897482 | 0.78 | CYP2D6 (0.49) | NAAAKDM4ECYP2D6CYP19A1CYP2C9 | |
| SCHEMBL4278696 | 0.77 | CYP2D6 (0.43) | NAAALTA4HPTGS2KDM4ECYP2D6 | |
| SCHEMBL5860857 | 0.77 | HSP90AA1 (0.39) | NAAALTA4HPTGS2KDM4EHSP90AA1 | |
| SCHEMBL9459435 | 0.77 | LTA4H (0.37) | NAAALTA4HPTGS2KDM4ECYP2D6 | |
| SCHEMBL14300674 | 0.77 | LTA4H (0.37) | NAAALTA4HPTGS2KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016055947-A1 | ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-04-14 | — | — | WO | claimed |
| WO-2016055947-A1 | ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | CMA1, ACE, AGTR1 | NAAA 973/4885LTA4H 182/4885PTGS2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.